Akums Gains DCGI Approval for Colchicine in Cardiovascular Indication, a First in India

A first-in-India regulatory clearance for a cardiovascular application of Colchicine positions Akums Drugs and Pharmaceuticals at the leading edge of a segment where DCGI-approved generics remain scarce. For QA directors and regulatory affairs leads tracking India's evolving cardiology generics landscape, the approval signals that the Drug Controller General of India is prepared to move on novel therapeutic indications for established molecules, a posture that carries direct implications for dossier strategy and submission timelines.

Colchicine, long established in gout and pericarditis management, has drawn renewed clinical interest following evidence supporting its anti-inflammatory mechanism in reducing cardiovascular events. Akums' approval marks the first time the molecule has received DCGI sanction specifically for cardiovascular use within India, extending the therapeutic label into a high-volume chronic-disease category. The approval broadens Akums' regulated-market portfolio and reinforces the company's positioning as a CDMO with credible domestic regulatory standing across multiple therapeutic areas.

For plant heads managing cardiovascular generics lines, the development is a reference point on how Indian manufacturers are navigating label expansions for off-patent molecules. Securing a first-in-India designation requires robust clinical data packages and manufacturing documentation aligned with Schedule M and applicable GMP standards, a compliance burden that, once cleared, creates a durable competitive position in the domestic market and strengthens the dossier foundation for regulated export markets.

The broader supply-chain read is that Indian CDMOs with DCGI-validated cardiovascular portfolios are increasingly well-placed to serve global demand for affordable cardiology generics, particularly as procurement agencies in regulated markets look to diversify sourcing. Akums' track record across formulation development and contract manufacturing gives the approval added weight as a signal of manufacturing readiness, not merely regulatory paperwork.

Regulatory affairs teams monitoring India's cardiology generics pipeline should note the DCGI's willingness to grant first-in-India status on indication extensions for established molecules, as this may inform the feasibility assessment for similar submissions across the sector.

Source: Media4Growth via Indian Pharma Post, 28 September 2026.